866 completed, 280 terminated, 232 recruiting, 142 unknown. 1785 Phase 2, 499 Phase 1, 56 Phase 3.
Follow Leukemia, Lymphoid: new trials by email Literature Review of Leukemia, Lymphoid trials Research Report on Leukemia, Lymphoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Suspended | Armaceutica, Inc. | 200 | 2028-02-21 | 2026-10-19 |
| Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 44 | 2027-08-04 | 2026-09-10 |
| CAR-T Immunotherapy Targeting CD19- ALL 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-07-01 | 2026-08-26 |
| Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-01-27 | 2026-10-07 |
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL Treatment with blinatumomab given subcutaneously. - Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | University of Alberta | 80 | 2027-01-02 | 2026-08-12 |
| CD34+ Transplants for Myeloid Malignancies Busulfan, Melphalan, Fludarabine - Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute | Phase 2 | Not yet recruiting | Guenther Koehne | 50 | 2027-01-01 | 2026-10-13 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Tacabrutideg, Sonrotoclax, Obinutuzumab - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 30 | 2027-01-01 | 2026-10-21 |
| A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia Zanubrutinib, Obinutuzumab, Sonrotoclax - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2026-12-31 | 2026-06-30 |
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2026-12-31 | 2026-08-26 |
| Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations Ibrutinib Oral Tablet, Venetoclax Oral Tablet, Epcoritamab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 44 | 2026-12-31 | 2026-07-31 |
| Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 35 | 2026-12-19 | 2026-05-12 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Zanubrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 95 | 2026-12-01 | 2026-09-14 |
| CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study MB-CART19.1 - Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 30 | 2026-12-01 | 2026-10-22 |
| A Trial to Evaluate the Efficacy and Safety of a Fitness-adapted Thera-py Approach With Either Continuous Zanubrutinib Monotherapy or Time-limited Zanubrutinib + Sonrotoclax in Older and/or Frail Patients With Treatment-naïve CLL Zanubrutinib, Sonrotoclax - CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | German CLL Study Group | 80 | 2026-12-01 | 2026-10-27 |
| Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Nemtabrutinib, Lisocabtagene Maraleucel - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2026-12-01 | 2026-10-29 |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 32 | 2026-11-15 | 2026-10-02 |
| Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor Nemtabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | Phase 2 | Not yet recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 32 | 2026-11-04 | 2026-10-30 |
Showing 20 of 1785. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (920) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (899) · Leukemia (468) · Leukemia, Myeloid, Acute (414) · Lymphoma, Non-Hodgkin (398) · Lymphoma (340) · Lymphoma, Follicular (321) · Lymphoma, Mantle-Cell (292) · Myelodysplastic Syndromes (289) · Lymphoma, Large B-Cell, Diffuse (279) · Burkitt Lymphoma (269) · Lymphoma, B-Cell, Marginal Zone (266) · Hodgkin Disease (237) · Multiple Myeloma (183) · Recurrence (175)
Hemic and Lymphatic Diseases (1785) · Neoplasms by Histologic Type (1778) · Immunoproliferative Disorders (1775) · Immune System Diseases (1774) · Lymphatic Diseases (1771) · Hematologic Diseases (1765) · Lymphoproliferative Disorders (1755) · Neoplasms (1720) · Leukemia (1317) · Pathological Conditions, Signs and Symptoms (1172) · Pathologic Processes (1165) · Disease Attributes (1133) · Chronic Disease (1068) · Leukemia, B-Cell (892)
Cyclophosphamide (380) · Rituximab (227) · fludarabine phosphate (190) · Methotrexate (172) · Cytarabine (159) · fludarabine (146) · Vincristine (126) · Dexamethasone (120) · Peripheral Blood Stem Cell Transplantation (118) · venetoclax (112) · Filgrastim (111) · Etoposide (108) · Mycophenolic Acid (103) · Whole-Body Irradiation (101) · Tacrolimus (99)
M.D. Anderson Cancer Center (145) · Fred Hutchinson Cancer Center (89) · National Cancer Institute (NCI) (86) · Memorial Sloan Kettering Cancer Center (39) · City of Hope Medical Center (31) · Masonic Cancer Center, University of Minnesota (29) · Mayo Clinic (29) · St. Jude Children's Research Hospital (24) · Institute of Hematology & Blood Diseases Hospital, China (22) · National Heart, Lung, and Blood Institute (NHLBI) (21) · German CLL Study Group (20) · Gruppo Italiano Malattie EMatologiche dell'Adulto (20) · Gilead Sciences (17) · H. Lee Moffitt Cancer Center and Research Institute (17) · Novartis Pharmaceuticals (16)
United States (1197) · China (169) · Italy (138) · Germany (125) · France (112) · Canada (105) · United Kingdom (94) · Spain (80) · Australia (68) · Belgium (52) · Netherlands (46) · Austria (44) · Poland (39) · South Korea (39) · Japan (38)
Elias Jabbour (10) · Brenda Sandmaier (9) · Alessandra Ferrajoli, MD (7) · Thomas E. Witzig, MD (6) · Ajay Gopal (5) · David Maloney (5) · Elias Jabbour, MD (5)
PMID 41671463, PMID 35622074, PMID 32499241, PMID 34515338, PMID 34398557, PMID 23524640, PMID 29358183, PMID 23065508, PMID 27209293, PMID 26182309, PMID 33242441, PMID 34048072, PMID 34608724, PMID 35007144, PMID 41843779, PMID 19141862, PMID 19826119, PMID 21527516, PMID 21623761, PMID 22133778, PMID 22289993, PMID 23547837, PMID 23886836, PMID 24443277, PMID 24862638, PMID 24990615, PMID 26432046, PMID 26472751, PMID 26813675, PMID 27503501, PMID 27601462, PMID 28054442, PMID 28714866, PMID 29358182, PMID 29437592, PMID 29618479, PMID 31023700, PMID 31196847, PMID 31208944, PMID 32209572, PMID 32619115, PMID 33067379, PMID 33496754, PMID 33741715, PMID 34267079, PMID 34353848, PMID 34432863, PMID 35422096, PMID 36442911, PMID 37227160
P30CA015704 (44), P30CA015083 (21), P30CA033572 (19), P01CA018029 (17), U10CA031946 (16), 2023 (13), P30CA016672 (13), 2015 (10), 2016 (10), 2018 (10), 2025 (10), P01CA078902 (10), U10CA032102 (10), 2009 (9), P30CA043703 (9)